Synthesis, characterization and in vitro evaluation of new composite bisphosphonate delivery systems

International Journal of Molecular Sciences

Volumn 15, Issue 9, 2014, Pages 16831-16847

  Kolmas, Joanna ^a   Sobczak, Marcin ^a   Olędzka, Ewa ^a   Nałęcz Jawecki, Grzegorz ^a   Dębek, Cezary ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Department of Elastomers and Rubber Technology   (Poland)

Author keywords

Bisphosphonates; Clodronate; Drug delivery systems; Hydroxyapatite; Polymeric biomaterials; Polyurethanes

Indexed keywords

CLODRONIC ACID; POLYCAPROLACTONE; POLYURETHAN; TRIACYLGLYCEROL LIPASE; BIOMATERIAL; BISPHOSPHONIC ACID DERIVATIVE; DRUG CARRIER; DRUG IMPLANT; HYDROXYAPATITE; NANOPARTICLE;

ALIIVIBRIO FISCHERI; ARTICLE; BIODEGRADATION; CANDIDA ANTARCTICA; CARBON NUCLEAR MAGNETIC RESONANCE; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; PROTOZOON; RING OPENING METATHESIS POLYMERIZATION; SCANNING ELECTRON MICROSCOPY; SYMPETRUM AMBIGUUM; TETRAHYMENA THERMOPHILA; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY; BIODEGRADABLE IMPLANT; CILIATE; DRUG EFFECTS; DRUG IMPLANT; EVALUATION STUDY; MATERIALS TESTING; POROSITY; SYNTHESIS;

ABSORBABLE IMPLANTS; ALIIVIBRIO FISCHERI; BIOCOMPATIBLE MATERIALS; CILIOPHORA; CLODRONIC ACID; DIPHOSPHONATES; DRUG CARRIERS; DRUG IMPLANTS; DURAPATITE; IN VITRO TECHNIQUES; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYURETHANES; POROSITY; TETRAHYMENA THERMOPHILA;

EID: 84907833364     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150916831     Document Type: Article

References (36)

1. Coleman, R. E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27, 165-176.
2. Holen, I.; Coleman, R. E. Bisphosphonates as treatment of bone metastases. Curr. Pharm. Des. 2010, 16, 1262-1271.
3. Coleman, R. E. Bisphosphonates: Clinical experience. Oncologist 2004, 9, 14-27.
4. Lipton, A. Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. J. Support. Oncol. 2004, 2, 205-220.
5. Von Moos, R. Ibandronate provides efficacy and safety in the treatment of metastatic bone disease. Eur. J. Cancer Suppl. 2006, 4, 13-18.
6. Russell, R. G.; Watts, N. B.; Ebetino, F. H.; Rogers, M. J. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 2008, 19, 733-759.
7. Russell, R. G. Bisphosphonates: The first 40 years. Bone 2011, 49, 2-11.
8. Padalecki, S. S.; Carreon, M.; Grubbs, B.; Cui, Y.; Guise, T. A. Androgen deprivation enhances bone loss and prostate cancer metastases to bone: Prevention by zoledronic acid. Oncology 2003, 17 (Suppl.), 32-54.
9. Rosen, L. S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M. A. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: A randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98, 1735-1744.
10. Barret-Lee, P.; Casbard, A.; Abraham, J.; Hood, K.; Coleman, R.; Simmonds, P.; Timmins, H.; Wheatley, D.; Grieve, R.; Griffiths, G.; et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: A randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014, 15, 114-122.
11. Tanvetyanon, T.; Stiff, P. J. Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. 2006, 17, 897-907.
12. Uhrich, K. E.; Cannizzaro, S. M.; Langer, R. S.; Shakesheff, K. Polymeric systems for controlled drug release. Chem. Rev. 1999, 99, 3181-3198.
13. Ouchi, T.; Ohya, Y. Macromolecular prodrugs. Prog. Polym. Sci. 1995, 20, 211-257.
14. Sobczak, M.; Olędzka, E.; Kołodziejski, W.; Kuźmicz, R. Pharmaceutical application of polymers. Polimery 2007, 52, 411-420.
15. Giger, E. V.; Castagner, B.; Leroux, J.-C. Biomedical applications of bisphosphonates. J. Control. Release 2013, 167, 175-188.
16. Karrholm, J.; Borssen, B.; Lowenhielm, G.; Snorrason, F. Does early micromotion of femoral stem prostheses matter? 4-7-Year stereoradiographic follow-up of 84 cemented prostheses. J. Bone Jt. Surg. Br. 1994, 76, 912-917.
17. Cremers, S.; Papapoulos, S. Pharmacology of bisphosphonates. Bone 2011, 49, 42-49.
18. Katsumi, H.; Takashima, M.; Sano, J.-I.; Nishiyama, K.; Kitamura, N.; Sakane, T.; Hibi, T.; Yamamoto, A. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: Evaluation of absorption, safety, and effects after intrapulmonary administration in rats. J. Pharm. Sci. 2011, 100, 3783-3792.
19. Bellido, T.; Plotkin, L. I. Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability. Bone 2011, 49, 50-55.
20. Gutman, D.; Golomb, G. Liposomal alendronate for the treatment of restenosis. J. Control. Release 2012, 161, 619-627.
21. Zeisberger, S. M.; Odermatt, B.; Marty, C.; Zehnder-Fjallman, A. H. M.; Ballmer-Hofer, K.; Schwendener, R. A. Clodronate-liposome-mediated depletion of tumour associated macrophages: A new and highly effective antiangiogenic therapy approach. Br. J. Cancer 2006, 95, 272-281.
22. Salzano, G.; Marra, M.; Porru, M.; Zappavigna, S.; Abbruzzese, A.; la Rotonda, M. I.; Leonetti, C.; Caraglia, M.; de Rosa, G. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int. J. Pharm. 2011, 403, 292-297.
23. Wang, G.; Mostafa, N. Z.; Incani, V.; Kucharski, C.; Uludag, H. Bisphosphonate decorated lipid nanoparticles designed as drug carriers for bone diseases. J. Biomed. Mater. Res. A 2012, 100, 684-693.
24. Cherng, J. Y.; Houa, T. Y.; Shih, M. F.; Talsma, H.; Hennink, W. E. Polyurethane-based drug delivery systems. Int. J. Pharm. 2013, 450, 145-162.
25. Errassifi, F.; Sarda, S.; Barroug, A.; Legrouri, A.; Sfihi, H.; Rey, C. Infrared, Raman and NMR investigations of risedronate adsorption on nanocrystalline apatites. J. Colloid Interface Sci. 2014, 420, 101-111.
26. Iafisco, M.; Palazzo, B.; Falini, G.; di Foggia, M.; Bonora, S.; Nicolis, S.; Casella, L.; Roveri, N. Adsorption and conformational change of myoglobin on biomimetic hydroxyapatite nanocrystals functionalized with alendronate. Langmuir 2008, 24, 4924-4930.
27. Josse, S.; Faucheux, C.; Soueidan, A.; Grimandi, G.; Massiot, D.; Alonso, B.; Janvier, P.; Laïb, S.; Pilet, P.; Gauthier, O.; et al. Novel materials for bisphosphonates delivery. Biomaterials 2005, 26, 2073-2080.
28. Cukrowski, I.; Popović, L.; Barnard, W.; Paul, S. O.; van Royen, P. H.; Liles, D. C. Modeling and spectroscopic studies of bisphosphonate-bone interactions. The Raman, NMR and crystallographic investigations of Ca-HEDP complexes. Bone 2007, 41, 668-678.
29. Alghamdi, H. S.; Bosco, R.; Both, S. K.; Iafisco, M.; Leeuwenburgh, S. C. G.; Jansen, J. A.; van den Beucken, J. J. J. P. Synergistic effect of bisphosphonates and calcium phosphate nanoparticles on peri-implant bone responses in osteoporotic rats, Biomaterials 2014, 35, 5482-5490.
30. Pascaud, P.; Errassifi, F.; Brouillet, F.; Sarda, S.; Barroug, A.; Legrouri, A.; Rey, C. Adsorption on apatitic calcium phosphates for drug delivery: Interaction with bisphosphonates molecules. J. Mater. Sci. Mater. Med. 2014, doi: 10. 1007/s10856-014-5218-0.
31. Sobczak, M. Enzyme-catalyzed ring-opening polymerization of cyclic esters in the presence of poly(ethylene glycol). J. Appl. Polym. Sci. 2012, 125, 3602-3609.
32. Sobczak, M.; Dębek, C.; Olędzka, E.; Nałęcz-Jawecki, G.; Kołodziejski, W. L.; Rajkiewicz, M. Segmented polyurethane elastomers derived from aliphatic polycarbonate and poly(ester-carbonate) soft segments for biomedical applications. J. Polym. Sci. A Polym. Chem. 2012, 50, 3904-3913.
33. Sobczak, M.; Nałęcz-Jawecki, G.; Kołodziejski, W. L.; Goś, P.; Żółtowska, K. Synthesis and study of controlled release of ofloxacin from polyester conjugates. Int. J. Pharm. 2010, 402, 37-43.
34. Gorna, K.; Gogolewski, S. In vitro degradation of novel medical biodegradable aliphatic polyurethanes based on ε-caprolactone and Pluronics® with various hydrophilicities. Polym. Degrad. Stab. 2002, 75, 113-122.
35. Sobczak, M.; Dębek, C.; Goś, P. Preparation and mechanical properties of PCL-based polyurethanes as potential biomaterials for short-term applications. E-Polymers 2010, 10, 1661-1669.
36. Asefnejad, A.; Khorasani, M. T.; Behnamghader, A.; Farsadzadeh, B.; Bonakdar, S. Manufacturing of biodegradable polyurethane scaffolds based on polycaprolactone using a phase separation method: Physical properties and in vitro assay. Int. J. Nanomed. 2011, 6, 2375-2384.